The earnings reports for the biggest of Big Pharma are all in. Bayer reported last week, making it possible to see how they stacked up as they came into the new year. There are no big surprises....
Bayer knows what a good launch can do; with blood thinner Xarelto and eye drug Eylea, it's had a couple of the recent best. Thanks to that pair of hot-selling meds, the German pharma raised the sales forecast for its new products by €2 billion late last week--and it's raising its marketing budget along with it.
Is Pfizer and Bristol-Myers Squibb's Eliquis really safer than its competitors? A recent analysis of FDA adverse events reports suggested that it is.
Blood thinner Xarelto and eye med Eylea pack a pretty good one-two-punch. Those new drugs helped Bayer's pharma sales climb 9.4% in 2013, and they're not stopping: They'll ultimately lead a group of 5 recently launched products to sales of €7.5 billion ($10.3 billion) or more, CEO Marijn Dekkers said Friday.
A rejuvenated R&D shop has given Bayer a spate of potential blockbusters, and CEO Marijn Dekkers wants to see more where that came from. The German drugmaker is planning to substantially increase its research budget over the next three years and set aside a boatload of cash for M&A.
Bayer is joining the growing number of drugmakers expanding production capacity in China but in Bayer's case, it is doing it with an acquisition. The German drugmaker is buying one of the top makers of over-the-counter drugs and herbal medicines in the country and getting a number of plants in the process.
Bayer already has a big footprint in China, where it's been selling drugs since the 1930s. But that footprint is about to get a bit bigger. The company is set to buy out China's Dihon Pharmaceutical Group, a company that specializes in OTC drugs--making it just the kind of pickup the German drugmaker's been scouting for.
Bayer has posted a fresh set of positive data on its hemophilia therapy BAY94-9027. But with a timeline that doesn't anticipate a regulatory filing until next year, at least one prominent analyst says that Biogen Idec still commands a lead in their race to the market.
Bayer's painkiller Aleve carries the same heart-risk warning as other nonsteroidal anti-inflammatories, or NSAIDs, like Motrin and Advil. And as far as an FDA review panel of experts is concerned, it should continue to.
Last week Novartis' vaccine unit posted yet another operating loss, extending its streak in the red to four years. Yet despite its well-known, long-term problems, suitors are reportedly circling the unit, with the potential of Bexsero and Menveo likely to be a factor attracting potential buyers.